Stem Cell Breast Augmentation vs SVF Breast Augmentation
以下の事実はすべて2つのエンティティページとその出典に基づきます。両方に記録のある項目を先に対比し、残りは並べて表示します。
概念
Stem Cell Breast AugmentationA consumer and marketing term for breast fat grafting enriched with stromal vascular fraction or adipose-derived cells. It is not a separate regulated procedure category.更新 2026年9月21日医療
SVF Breast AugmentationSVF breast augmentation is breast fat grafting in which the injected fat is enriched with the patient's own stromal vascular fraction.更新 2026年9月21日両者の関係Stem Cell Breast Augmentation — 一般に指す施術 → SVF Breast Augmentation
共通項目
両側に記録あり 0件この2つに共通して記録された項目はまだありません。それぞれの検証済みの事実は以下のとおりです。
それぞれの事実
どちらか一方にのみ記録されている検証済みの事実です。
Stem Cell Breast Augmentation
まだ検証された値がありません
SVF Breast Augmentation
DefinitionAutologous fat grafting in which SVF isolated from part of the aspirated fat is recombined with the remaining fat before injection, turning progenitor-poor aspirated fat into progenitor-rich fat
First described for cosmetic breast augmentationYoshimura K et al., Aesthetic Plastic Surgery 32(1):48–55 (2008); 40 patients, mean ~270 mL fat injected per breast, final gain 100–200 mL
Complications in original seriesCysts (<12 mm) on MRI in 2 patients; microcalcification on mammogram in 2 patients at 24 months; 1 case of sternal fibrosis
Breast augmentation meta-analysis (Li & Chen)6 studies, 353 patients: CAL had higher fat survival (SMD 1.79, 95% CI 0.28–3.31); complications did not differ significantly (OR 1.34); the SVF-enriched subgroup showed no survival difference
Meta-analysis across recipient sites (Sutar et al.)15 studies: graft survival favored enriched grafts (SMD 2.44), with very high heterogeneity (I² = 97.19%); benefit was context-dependent
US FDA positionAdipose-derived SVF fails the minimal-manipulation criterion (21 CFR 1271.10(a)(1)) and needs an IND or an approved BLA as a drug/biologic
US court ruling on same-day SVFNinth Circuit (Sept 2024) held SVF procedures do not qualify for the same-surgical-procedure exemption; the Supreme Court declined review on 2025-10-15
Korea: Advanced Regenerative Bio Act amendmentEffective 2025-02-21: regenerative-medicine treatment allowed only for serious, rare or intractable diseases, at designated institutions, with review-committee approval of treatment plans
Reported safety concernsCyst formation 6.9% with automated vs 1.6% with manual isolation in cited data; theoretical oncogenic concern from VEGF/FGF signalling; long-term oncologic data insufficient
Method standardizationNo standardized CAL protocol; multiple isolation systems in use (e.g., Celution, Medikhan, Fatstem, Mystem)
Reported outcome (SC301-authored, 2023)Average injected volume 162.35 mL (left breast); retention 78.65% (3 mo), 77.17% (6 mo), 77.48% (18 mo, n=102)
Reported outcome (SC301-authored, 2020)In 105 patients, engraftment 85.1% (1 mo), 75.1% (3 mo), 73.7% (6 mo); patients receiving >60 million ADSC had 90.5% vs 68.9% for <60 million
Evidence levelSingle-center, provider-authored series; no independent randomized controlled data identified as of 2026-09